Baillie Gifford & Co
CHRS icon

Baillie Gifford & Co’s Coherus Oncology CHRS Stock Holding History

Baillie Gifford & Co’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,585
Closed -$10.8K – 326
2023
Q1 		$10.8K Hold
1,585
– – ﹤0.01% 394
2022
Q4 		$12.6K Hold
1,585
– – ﹤0.01% 395
2022
Q3 		$15K Buy
1,585
+154
+11% +$1.56K ﹤0.01% 365
2022
Q2 		$10K Hold
1,431
– – ﹤0.01% 408
2022
Q1 		$18K Hold
1,431
– – ﹤0.01% 374
2021
Q4 		$23K Sell
1,431
-174
-11% -$3.04K ﹤0.01% 359
2021
Q3 		$26K Sell
1,605
-202
-11% -$2.96K ﹤0.01% 332
2021
Q2 		$25K Hold
1,807
– – ﹤0.01% 336
2021
Q1 		$26K Buy
1,807
+104
+6% +$1.77K ﹤0.01% 313
2020
Q4 		$30K Buy
+1,703
New +$30.3K ﹤0.01% 292

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Baillie Gifford & Co's CHRS Position: Q2 2023 in Review

Baillie Gifford & Co sold out of Coherus Oncology (CHRS) in Q2 2023, closing a stake of 1,585 shares — an estimated $10.8K sold.

Baillie Gifford & Co first reported a position in CHRS in Q4 2020 and held it in 10 quarters. The position peaked at $30K in Q4 2020. 161 funds tracked by Wall St. Rank hold CHRS as of Q2 2023.

  • Baillie Gifford & Co reported no remaining Coherus Oncology position as of Q2 2023 after selling out during the quarter.
  • Baillie Gifford & Co sold 1,585 Coherus Oncology shares in Q2 2023, an estimated $10.8K.
  • Baillie Gifford & Co first reported a position in Coherus Oncology in Q4 2020 and held it in 10 quarters.
  • Baillie Gifford & Co's Coherus Oncology position peaked at $30K in Q4 2020.
  • 161 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2023.

Based on Baillie Gifford & Co's 13F filing for Q2 2023, filed 28 Jul 2023.